Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History PRLD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics PRLD

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Prelude Therapeutics Inc

PRLD
Current price
0.89 USD +0.027 USD (+3.15%)
Last closed 0.84 USD
ISIN US74065P1012
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 44 823 992 USD
Yield for 12 month -77.65 %
1Y
3Y
5Y
10Y
15Y
PRLD
21.11.2021 - 28.11.2021

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. Address: 175 Innovation Boulevard, Wilmington, DE, United States, 19805

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.75 USD

P/E Ratio

Dividend Yield

Financials PRLD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures PRLD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+7 000 000 USD

Last Year

Current Quarter

Last Quarter

+4 000 000 USD

Current Year

+7 000 000 USD

Last Year

-1 169 000 USD

Current Quarter

Last Quarter

+4 000 000 USD
EBITDA -138 196 000 USD
Operating Margin TTM -1 999.67 %
Price to Earnings
Return On Assets TTM -45.05 %
PEG Ratio
Return On Equity TTM -81.44 %
Wall Street Target Price 3.75 USD
Revenue TTM 7 000 000 USD
Book Value 1.83 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM 7 000 000 USD
Earnings per share -1.68 USD
Diluted Eps TTM -1.68 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation PRLD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM 6.40
Enterprise Value EBITDA -0.54
Price Book MRQ 0.43

Technical Indicators PRLD

For 52 Weeks

0.61 USD 6.80 USD
50 Day MA 0.90 USD
Shares Short Prior Month 945 733
200 Day MA 1.11 USD
Short Ratio 4.77
Shares Short 841 037
Short Percent 11.40 %